Amplification of PRR11 was predominant in breast cancer, Pleural Mesothelioma, cholangiocarcinoma, and pheochromocytoma, while deep deletion was prevalent in prostate cancer. This evidence concerns the gene PRR11 and Familial prostate cancer.